Anifrolumab In Systemic Lupus Erythematosus With Renal Involvement: National Multicenter Registry In Clinical Practice (LUPUS 2026) - Feb 17, 2026 - Abstract #PO:09:247; 24; Pres time: Mar 6, 2026; 07:30 AM - 07:30 PM; Location: Poster Area; "All of them had received belimumab, and 15 mycophenolate mofetil. The standard ANI regimen was 300 milligrams every 4 weeks, except in two patients who received loading doses (900 milligrams every 4 weeks for 3 months, then 300 milligrams every 4 weeks).In addition to corticosteroids, ANI was administered concomitantly with antimalarials (n=16), mycophenolate mofetil (n=11), tacrolimus (n=4), azathioprine (n=2), methotrexate (n=1), and voclosporin (n=1)...The prednisone dose was decreased from 9.2±7.9 mg/day to 3.3±2 mg/day (p= 0.1).Abstract PO:09:247 Figures and Table Conclusions To our knowledge, this is the first real-life study of ANI in LN. In refractory patients to multiple immunosuppressive therapies, we observed a rapid and maintained effectiveness in SLE activity and renal manifestations, with a good safety profile."
Clinical • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
|
|
Vanesa Calvo Del Río; Carmen Secada-Gómez; Blanca García Magallon; Deseada Palma Sanchez; Andrea García Valle; Irati Urionaguena Onaindia; Adrián Mayo Juanatey; Paul Hernandez Velasco; Guillermo González Arribas; Ana Pareja Martinez; Montserrat Corteguera; Guillén Sada Urmeneta; Paz Collado; Jose Luís Tandaipan; Juan Roberto Miguélez Sanchez; Adrián Martín-Gutiérrez; Ricardo Blanco
|